These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8295522)

  • 1. Iron overload? In sickle cell disease?
    Day S; Dancy R; Kelly K; Wang W
    MCN Am J Matern Child Nurs; 1993; 18(6):330-5. PubMed ID: 8295522
    [No Abstract]   [Full Text] [Related]  

  • 2. Iron burden in sickle cell anemia.
    O'Brien RT
    J Pediatr; 1978 Apr; 92(4):579-82. PubMed ID: 633016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose intravenous chelation therapy with deferoxamine.
    Cohen A; Mizanin J; Schwartz E
    Prog Clin Biol Res; 1989; 309():125-31. PubMed ID: 2780746
    [No Abstract]   [Full Text] [Related]  

  • 4. Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship.
    Silliman CC; Peterson VM; Mellman DL; Dixon DJ; Hambidge KM; Lane PA
    J Lab Clin Med; 1993 Jul; 122(1):48-54. PubMed ID: 8320490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of iron overload due to repeated transfusions with subcutaneous infusions of desferrioxamine (author's transl)].
    Girot R; Thévenin M; Bouveret JP; Jeannel F; Rymer JC
    Arch Fr Pediatr; 1980 Apr; 37(4):241-7. PubMed ID: 7406638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.
    Vichinsky E; Pakbaz Z; Onyekwere O; Porter J; Swerdlow P; Coates T; Lane P; Files B; Mueller BU; Coïc L; Forni GL; Fischer R; Marks P; Rofail D; Abetz L; Baladi JF
    Acta Haematol; 2008; 119(3):133-41. PubMed ID: 18408362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel delivery system for continuous desferrioxamine infusion in transfusional iron overload.
    Araujo A; Kosaryan M; MacDowell A; Wickens D; Puri S; Wonke B; Hoffbrand AV
    Br J Haematol; 1996 Jun; 93(4):835-7. PubMed ID: 8703813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desferrioxamine-chelatable iron (DCI), a component of serum non-transferrin-bound iron (NTBI) used for assessing iron chelation therapy.
    Breuer W; Ermers MJ; Pootrakul P; Abramov A; Hershko C; Cabantchik ZI
    Transfus Sci; 2000 Dec; 23(3):241-2. PubMed ID: 11099901
    [No Abstract]   [Full Text] [Related]  

  • 9. Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine.
    Hoffbrand AV; Gorman A; Laulicht M; Garidi M; Economidou J; Georgipoulou P; Hussain MA; Flynn DM
    Lancet; 1979 May; 1(8123):947-9. PubMed ID: 87616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of post-transfusion iron overload by deferoxamine].
    de Montalembert M; Llados A; Hannedouche T; Girot R
    Arch Fr Pediatr; 1989 Feb; 46(2):99-105. PubMed ID: 2735804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Deferoxamine in hemosiderosis. Fecal iron excretion during continuous subcutaneous infusion].
    Krüger N; Kijewski H; König R; Tillmann W; Schröter W
    Dtsch Med Wochenschr; 1984 Nov; 109(44):1682-5. PubMed ID: 6489181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of iron overload in adults with continuous parenteral desferrioxamine.
    Cooper B; Bunn HF; Propper RD; Nathan DG; Rosenthal DS; Moloney WC
    Am J Med; 1977 Dec; 63(6):958-66. PubMed ID: 605917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Isoferritin profile of serum ferritin in patient's with secondary hemosiderosis treated with desferrioxamine].
    Mariańska B; Eber M; Oberling F
    Acta Haematol Pol; 1982; 13(3-4):65-72. PubMed ID: 7184299
    [No Abstract]   [Full Text] [Related]  

  • 14. [Guidelines for diagnosis and treatment of secondary iron overload in patients with congenital anemia].
    Cario H; Grosse R; Janssen G; Jarisch A; Meerpohl J; Strauss G;
    Klin Padiatr; 2010 Nov; 222(6):399-406. PubMed ID: 20862634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MR evaluation of liver iron overload.
    Hernandez RJ; Sarnaik SA; Lande I; Aisen AM; Glazer GM; Chenevert T; Martel W
    J Comput Assist Tomogr; 1988; 12(1):91-4. PubMed ID: 3335677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnosis and therapy of iron overload with desferrioxamine].
    Andres J; Stobbe H
    Z Gesamte Inn Med; 1984 Apr; 39(8):167-9. PubMed ID: 6730593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pelvic osteomyelitis in a sickle-cell patient receiving deferoxamine.
    McLean TW; Kurth S; Gee B
    Am J Hematol; 1996 Dec; 53(4):284-5. PubMed ID: 8948680
    [No Abstract]   [Full Text] [Related]  

  • 18. Transfusional hemosiderosis in sickle cell anemia: another cause of an echogenic pancreas.
    Flyer MA; Haller JO; Sundaram R
    Pediatr Radiol; 1993; 23(2):140-2. PubMed ID: 8516039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron overload in cardiac valvular disease and pure red cell aplasia: treatment with desferrioxamine.
    Hehlmann R; Schmitz H; Krüger K
    Int J Cardiol; 1984 Jun; 5(6):749-53. PubMed ID: 6235195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose deferoxamine treatment (intravenous) for thalassaemia patients with cardiac complications.
    Ghader FR; Kousarian M; Farzin D
    East Mediterr Health J; 2007; 13(5):1053-9. PubMed ID: 18290397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.